false
0001734005
0001734005
2026-09-04
2026-09-04
0001734005
dei:FormerAddressMember
2026-09-04
2026-09-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 4, 2026
Niki BioSolutions, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware |
|
001-38764 |
|
42-3265309 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
| 116 Village Boulevard, Suite 200, Princeton, NJ 08540 |
| (Address of Principal Executive Offices, including zip code) |
Registrant’s Telephone Number, Including
Area Code: 609-951-2222
Aptorum Group Limited
17 Hanover Square
London W1S 1BN, United Kingdom
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common stock, par value $0.0001 per share |
|
NIKI |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
In connection with the previously announced merger
transaction, Mr. Ian Huen and Alidad Mireskandari became the CEO and COO, respectively of Niki BioSolutions, Inc. (the “Company”).
On September 1, 2026, the Company entered into separate agreements with each of Mr. Huen and Mr. Mireskandari, each with an August 1,
2026 effective date.
Pursuant to the appointment letter for Mr. Huen
(the “Huen Appointment letter”), Mr. Huen shall serve as the Company’s Chief Executive Officer. The Huen Appointment
letter has an initial term of six months, subject to renewal by mutual agreement. His monthly base salary is HKD 210,000, which is approximately
USD26,800 based on an exchange rate of 7.84 as of the date of this Report. He may also be entitled to a discretionary bonus, subject to the
discretion of the Board and approval of the Compensation Committee. In addition, Mr. Huen is eligible to receive share bonuses, with
the amount, timing and vesting terms to be determined by the Company and approved by the Compensation Committee, and an option to purchase
shares pursuant to the Company’s Share Option Plan. Either Mr. Huen or the Company may terminate his appointment upon not less
than one month’s prior written notice, and the Company may terminate his appointment immediately upon the occurrence of certain
specified events.
Pursuant to the employment agreement with Mr.
Mireskandari (the “Mireskandari Employment Agreement”), he will serve as President and Chief Operating Officer of the
Company. Under the Mireskandari Employment Agreement, Mr. Mireskandari is entitled to an annual base salary of $320,000, of which $35,000
will be deferred until the Company receives certain capital investments resulting in proceeds of $3,000,000 and which will increase to
$350,000, if the Company receives aggregate capital investments of $5,000,000 during his employment. Mr. Mireskandari is also eligible
for an annual performance bonus of up to 50% of his base salary and was granted 20,000 restricted stock units (RSUs) vesting immediately
at the closing of the merger transaction and options to purchase 800,000 shares of the Company’s common stock under the Company’s
2026 Equity Incentive Plan, subject to the vesting conditions set forth in the Mireskandari Employment Agreement.
The foregoing descriptions of the Huen
Appointment Letter and Mireskandari Employment Agreement do not purport to be complete and are qualified in their entirety by
reference to the full text of such agreements, which are filed as Exhibits 10.1 and 10.2, to this Current Report on Form 8-K and
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit |
|
Description |
| 10.1 |
|
Appointment letter for Ian Huen, dated August 1, 2026 |
| 10.2 |
|
Employment Agreement between Alidad Mireskandari and Niki BioSolutions, Inc dated September 1, 2026 |
| 104 |
|
Cover Page Interactive Data File, formatted in Inline XBRL |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: September 4, 2026
| |
NIKI BIOSOLUTIONS, INC. |
| |
|
|
| |
By: |
/s/ Ian Huen |
| |
|
Ian Huen |
| |
|
Chief Executive Officer |
